AUSTIN, Texas, April 4, 2011 /PRNewswire/ -- (Nasdaq: VRML) – Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available ...

Vermillion, Inc. has announced that it has agreed with Quest Diagnostics to extend the Strategic Alliance Agreement between the parties through October, 2009. This extension will enable the companies ...

* VERMILLION INC - ON MARCH 11, CO, UNIT AND QUEST DIAGNOSTICS, ENTERED INTO AMENDMENT NO. 4 TO TESTING AND SERVICES AGREEMENT - SEC FILING Sign up here. * VERMILLION INC - PURPOSE OF AMENDMENT WAS TO ...

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second ...

Vermillion Inc. and Quest Diagnostics Inc. on Tuesday released OVA1, a test meant to help doctors determine if a woman suspected of having ovarian cancer should have exploratory surgery by a ...

LOS ANGELES, Sept 11 (Reuters) - The U.S. Food and Drug Administration on Friday said it has approved a blood test for detecting ovarian cancer in a pelvic mass that already is known to require ...

MADISON, N.J. and FREMONT, Calif., Sept. 11 The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a ...